![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ISRAEL'S OPTIMATA IN PHARMACEUTICAL COLLABORATION WITH LILLY
ISRAEL'S OPTIMATA IN PHARMACEUTICAL COLLABORATION WITH LILLY
March 29, 2006
Optimata Ltd., a science-based, interdisciplinary company, dedicated to the development of predictive bio simulation technologies, announced the completion of the first phase of a pilot collaboration project with Eli Lilly & Co. The project uses Optimata's Virtual Patient Technology to assist in the clinical trial design of a novel anti-cancer cytotoxic compound. "We are excited to have this opportunity to work with a leading pharmaceutical manufacturer like Eli Lilly," said Guy Malchi, President of Optimata. The virtual patient technology is a computer generated method that predicts how patients will respond to a compound.
Israel121c.org (http://www.israel21c.org/bin/en.jsp?enDispWho=InThePress&enPage=BlankPage&enDisplay=view&enDispWhat=Zone&enZone=InThePress&Date=03/29/06)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct